LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Lineage Cell Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.95−0.03 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $249.13M
- P/E (TTM)
- –
- Dividend yield
- –
Lineage Cell Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenues [Member] | $13.61M | $8.15M | $7.59M | $13.37M | $1.12M | – | – | – | – | – | 93.5% | +67.0% |
| Event Based Milestones and Other Collaborative Revenue [Member] | $7.16M | – | – | – | – | – | – | – | – | – | 49.2% | – |
| Upfront License Fees [Member] | $6.45M | $8.15M | $7.59M | $13.37M | $452.00K | – | – | – | – | – | 44.3% | -20.9% |
| Royalties, License and Other Revenues [Member] | $947.00K | $1.35M | $1.36M | $1.34M | – | – | – | – | – | – | 6.5% | -29.9% |
| Grant [Member] | – | – | – | – | – | $1.05M | $2.04M | $3.57M | $1.67M | – | – | – |
| Royalties From Product Sales and License Fees [Member] | – | – | – | – | – | $773.00K | $1.22M | $392.00K | $389.00K | – | – | – |
| Subscription and Advertisement Revenues [Member] | – | – | – | – | – | – | – | $691.00K | $1.40M | – | – | – |
| Sale of Research Products and Services [Member] | – | – | – | – | – | – | $257.00K | $333.00K | $8.00K | – | – | – |
| Royalty [Member] | – | – | – | – | $2.78M | $773.00K | – | – | – | – | – | – |
| Royalties, license and other revenues [Member] | – | – | $1.36M | $1.34M | $2.78M | $773.00K | – | – | – | – | – | – |
| Grant Revenues [Member] | – | – | – | – | $445.00K | $1.05M | – | – | – | – | – | – |
| Event Based Development Milestones [Member] | – | – | – | – | $123.00K | – | – | – | – | – | – | – |
| Reimbursements Cost Sharing Payments [Member] | – | – | – | – | $545.00K | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US [Member] | $2.50M | $0 | – | – | – | – | – | – | – | – | 17.2% | – |
| Domestic [Member] | – | – | – | – | – | – | – | – | – | $4.50M | – | – |
| Asia [Member] | – | – | – | – | – | – | – | – | – | $1.43M | – | – |
| Foreign [Member] | – | – | – | – | $446.00K | $666.00K | $1.42M | $3.18M | $1.81M | $1.43M | – | – |
| United States [Member] | – | – | – | – | – | – | – | – | $1.65M | $4.50M | – | – |
| United States | – | – | – | $14.70M | $3.90M | $1.16M | $2.09M | $1.80M | $1.65M | – | – | – |
From the segment and revenue-disaggregation notes of Lineage Cell Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.